Tag Archives: Cosme Ordonez

Cardiff Oncology (CRDF) Gets a Buy Rating from Noble Financial

In a report released today, Cosme Ordonez from Noble Financial reiterated a Buy rating on Cardiff Oncology (CRDF – Research Report), with a price target of $23.00. The company’s shares closed last Thursday at $2.53. According to TipRanks.com, Ordonez is

Noble Financial Keeps a Buy Rating on PDS Biotechnology (PDSB)

Noble Financial analyst Cosme Ordonez reiterated a Buy rating on PDS Biotechnology (PDSB – Research Report) today and set a price target of $5.45. The company’s shares closed last Monday at $0.95, close to its 52-week low of $0.62. According

Noble Financial Thinks ProMIS Neurosci’s Stock is Going to Recover

ProMIS Neurosci (PMN – Research Report) has received a rating update from a Wall Street analyst yesterday. The Healthcare company, ProMIS Neurosci (TSX: PMN) has just received a rating update from a Wall Street analyst. According to TipRanks.com, Ordonez is

ProMIS Neurosci (PMN) Receives a Buy from Noble Financial

A Wall Street analyst has provided a review for the Healthcare company today, but retained the same rating on the stock. Analyst Cosme Ordonez from Noble Financial remains bullish on ProMIS Neurosci (PMN – Research Report) and has a C$1

Genprex Inc (GNPX) Initiated with a Buy at Noble Financial

Noble Financial analyst Cosme Ordonez initiated coverage with a Buy rating on Genprex Inc (GNPX – Research Report) on April 26 and set a price target of $5. The company’s shares closed on Friday at $1.78, close to its 52-week

ProMIS Neurosci (PMN) Gets a Buy Rating from Noble Financial

In a new note to investors on February 14, an analyst has provided a rating update for ProMIS Neurosci (PMN – Research Report). The company received a Buy on February 14 from Noble Financial’s analyst Cosme Ordonez, with a C$1